Table 1

Baseline demographics and disease characteristics

Variable	Any ADA exposure (N=311)
Sex, n (%) male	233 (74.9)
Race, n (%) white	299 (96.1)
Age, mean (SD) years	42.3 (11.6)
HLA-B27+, n (%)	245 (78.8)
Disease duration, mean (SD) years	11.00 (9.5)
Abnormal CRP, n (%) ≥0.49 mg/dl	211 (67.8)
BASDAI, mean (SD) cm (0–10 VAS)	6.3 (1.7)
Patient global assessment, mean (SD) mm (0–100 VAS)^*	63.6 (20.9)
Physician global assessment, mean (SD) mm (0–100 VAS)^*	57.3 (18.6)
Total back pain, mean (SD) mm (0–100 VAS)	65.3 (21.1)
BASFI, mean (SD) mm (0–100 VAS)	53.8 (22.1)
Inflammation, mean (SD) cm (0–10 VAS)^†	6.7 (2.0)
≥1 syndesmophyte, n (%)^‡	188 (85.8)

↵* N=310.
↵† Mean of BASDAI question 5 and 6.
↵‡ N=219.
ADA, adalimumab; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; CRP, C-reactive protein; HLA, human leucocyte antigen; VAS, visual analogue scale.